Taysha Gene Therapies (NASDAQ:TSHA) Announces Earnings Results, Beats Estimates By $0.03 EPS

Taysha Gene Therapies (NASDAQ:TSHA) announced its quarterly earnings results on Thursday. The company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.03, FiscalAI reports.

Here are the key takeaways from Taysha Gene Therapies’ conference call:

• All 33 treated patients cleared the acute post-dosing safety monitoring period, with no severe treatment-related serious adverse events or dose-limiting toxicities reported as of the November data cutoff. Management said TSHA-102 remains generally well tolerated across the trials.
• Taysha completed its BLA-enabling commercial-scale manufacturing campaign, with batches meeting predefined specifications and comparability criteria. The company said single-digit empty capsid levels and favorable yields could support product quality and efficient manufacturing, though it still plans to discuss the data and CMC strategy with the FDA.
• Taysha expects to report top-line results from the REVEAL pivotal trial’s six-month interim analysis and FDA feedback on the potential BLA pathway in the first half of 2027. Filing on six-month data could accelerate submission by at least two quarters, but the FDA has not yet agreed to that approach; the company said it would also share 12-month data.
• Taysha reported $422.8 million in cash and cash equivalents at September 30, which it expects to fund planned operations into the second half of 2028. Quarterly R&D and G&A expenses rose year over year, and net loss increased to $39.1 million from $32.7 million.
• The company said it has advanced launch preparations, including payer discussions, site readiness, and trade and distribution planning, and expects no supply constraint at launch. It also plans to nominate another CNS gene therapy candidate and begin preclinical work in the first half of 2027.

Taysha Gene Therapies Stock Performance

NASDAQ TSHA opened at $4.21 on Friday. The firm has a 50-day moving average price of $4.52 and a two-hundred day moving average price of $5.28. Taysha Gene Therapies has a 12-month low of $3.45 and a 12-month high of $7.30. The company has a market capitalization of $1.37 billion, a P/E ratio of -10.02 and a beta of 1.36. The company has a quick ratio of 17.76, a current ratio of 17.76 and a debt-to-equity ratio of 0.13.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Taysha Gene Therapies in a report on Monday, September 21st. Wolfe Research began coverage on Taysha Gene Therapies in a research note on Thursday, September 17th. They set an “outperform” rating on the stock. Finally, The Goldman Sachs Group lifted their price target on Taysha Gene Therapies from $11.00 to $13.00 and gave the stock a “buy” rating in a report on Tuesday, July 21st. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Taysha Gene Therapies currently has a consensus rating of “Buy” and an average target price of $12.77.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies is a biotechnology company focused on developing gene therapies for rare, genetically driven diseases. Based in Dallas, Texas, the company was founded in 2019 and has built its programs around adeno-associated virus delivery technology. The company’s lead program, TSHA-102, is an investigational gene therapy being developed for Rett syndrome, a rare neurological disorder. Taysha’s research has also included gene therapy programs for other rare diseases, including giant axonal neuropathy.